Investigation of Varicella zoster Virus Specific Immune Response for Prevention of Shingles in people with Diabetes.

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K08759
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Epidemiology and preventive medicine
• Research Institution: The Tazuke Kofukai
• Principal Investigator: HATA Atsuko 公益財団法人田附興風会, 医学研究所 第4研究部, 研究主幹 (70321685)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: 水痘帯状疱疹ワクチン / 糖尿病 / 細胞性免疫 / 液性免疫 / IFN-γ アッセイ / 同時接種 / 23価肺炎球菌ワクチン

Outline of Final Research Achievements

Cell-mediated immunity against live varicella-zoster vaccine with 23 valent pneumococcal polysaccharide vaccine simultaneously for people with diabetes aged 50 years or over resulted in a low response assessed by varicella-zoster virus (VZV) antigen skin test. We changed the method and found that VZV-specific cell-mediated immunity after varicella-zoster vaccination in healthy adults can be evaluated by whole blood IFN-γ assay by VZV antigen stimulation. A randomized double blind placebo-controlled trial with varicella-zoster vaccine and placebo in people with diabetes over the age of 50 years was conducted. VZV specific cell-mediated immunity was assessed by this whole blood IFN-γ assay and humoral immunity and safety to the varicella-zoster vaccine were also evaluated. 85 people were registered by June 2018, the final blood sampling one year after the last vaccination is scheduled to be completed in July 2018.

Free Research Field

ウイルス免疫学